Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer

Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers Ročník 15; číslo 2; s. 504
Hlavní autoři: Chhouri, Houssein, Alexandre, David, Grumolato, Luca
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 13.01.2023
MDPI
Témata:
Animals
Antitumor agents
Cancer therapies
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Clinical trials
Drug tolerance
Epidermal growth factor
Epidermal growth factor receptors
Exons
Growth factors
Hepatocyte Growth Factor
Humans
Kinases
Life Sciences
Ligands
Lung cancer
Lung Neoplasms
Metastasis
Mice
Mutation
Non-small cell lung carcinoma
Protein Kinase Inhibitors
Protein-tyrosine kinase
Proto-Oncogene Proteins c-met
Response rates
Review
Small cell lung carcinoma
Tumors
non-small cell lung cancer
targeted therapy
EGFR-TKI
drug resistance
drug tolerant persister cells
cellular barcoding
lung cancer
preclinical models
targeted therapies
transcriptomic
hepatocyte growth factor
tyrosine kinase receptor
ISSN:2072-6694, 2072-6694
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the clonal evolution of these subpopulations in response to anti-cancer drugs. In this review, we provide an overview of the currently available treatment options for NSCLC, focusing on EGFR targeted therapy, and discuss the common mechanisms of resistance to EGFR-TKIs. We also review the characteristics of drug-tolerant persister (DTP) cells and the mechanistic basis of drug tolerance in EGFR-mutant NSCLC. Lastly, we address how cellular barcoding can be applied to investigate the response and the behavior of DTP cells upon EGFR-TKI treatment.
AbstractList Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the clonal evolution of these subpopulations in response to anti-cancer drugs. In this review, we provide an overview of the currently available treatment options for NSCLC, focusing on EGFR targeted therapy, and discuss the common mechanisms of resistance to EGFR-TKIs. We also review the characteristics of drug-tolerant persister (DTP) cells and the mechanistic basis of drug tolerance in EGFR-mutant NSCLC. Lastly, we address how cellular barcoding can be applied to investigate the response and the behavior of DTP cells upon EGFR-TKI treatment.
Simple SummaryLung cancer is the major cause of cancer-related deaths worldwide. The development of targeted therapies has dramatically improved the outcome of lung cancer patients. However, despite an initial response, tumors almost invariably relapse as a result of acquired resistance. In this review, we discuss how lung cancer cells become resistant or tolerant to targeted therapy.AbstractNon-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the clonal evolution of these subpopulations in response to anti-cancer drugs. In this review, we provide an overview of the currently available treatment options for NSCLC, focusing on EGFR targeted therapy, and discuss the common mechanisms of resistance to EGFR-TKIs. We also review the characteristics of drug-tolerant persister (DTP) cells and the mechanistic basis of drug tolerance in EGFR-mutant NSCLC. Lastly, we address how cellular barcoding can be applied to investigate the response and the behavior of DTP cells upon EGFR-TKI treatment.
Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the clonal evolution of these subpopulations in response to anti-cancer drugs. In this review, we provide an overview of the currently available treatment options for NSCLC, focusing on EGFR targeted therapy, and discuss the common mechanisms of resistance to EGFR-TKIs. We also review the characteristics of drug-tolerant persister (DTP) cells and the mechanistic basis of drug tolerance in EGFR-mutant NSCLC. Lastly, we address how cellular barcoding can be applied to investigate the response and the behavior of DTP cells upon EGFR-TKI treatment.Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the clonal evolution of these subpopulations in response to anti-cancer drugs. In this review, we provide an overview of the currently available treatment options for NSCLC, focusing on EGFR targeted therapy, and discuss the common mechanisms of resistance to EGFR-TKIs. We also review the characteristics of drug-tolerant persister (DTP) cells and the mechanistic basis of drug tolerance in EGFR-mutant NSCLC. Lastly, we address how cellular barcoding can be applied to investigate the response and the behavior of DTP cells upon EGFR-TKI treatment.
Author Grumolato, Luca
Chhouri, Houssein
Alexandre, David
AuthorAffiliation Univ Rouen Normandie, Inserm, NorDiC UMR 1239, 76000 Rouen, France
AuthorAffiliation_xml – name: Univ Rouen Normandie, Inserm, NorDiC UMR 1239, 76000 Rouen, France
Author_xml – sequence: 1
  givenname: Houssein
  surname: Chhouri
  fullname: Chhouri, Houssein
– sequence: 2
  givenname: David
  surname: Alexandre
  fullname: Alexandre, David
– sequence: 3
  givenname: Luca
  orcidid: 0000-0001-8231-3032
  surname: Grumolato
  fullname: Grumolato, Luca
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36672453$$D View this record in MEDLINE/PubMed
https://hal.science/hal-05043716$$DView record in HAL
BookMark eNp1kstP3DAQh60KVCjl3FtlqRc4pDh2YieXSqsVj0pLK9HcLccZ7xol9mInSPz3OCxUdKX64Oc3v3l4PqED5x0g9CUn3xmryYVWTkOIeUkoKUnxAR1TImjGeV0cvNsfodMY70kajOWCi4_oiHEuaFGyY2RuQW-Us3GI2Bu80A-TDdDhO4g2jrMDrFyHG99DeDmNHl9eX93hRoU1jIlsNull-4Stw7-8y_4Mqu_xEtK0mtwaL1-C_IwOjeojnL6uJ6i5umyWN9nq9_XP5WKV6ZLmY9bRmjDgbVu0ojPatBwAeN0qY2gNNTAGois7wQooi0KZnJUiZQ9g8rYiHTtBP3ay26kdoNPgxqB6uQ12UOFJemXlvy_ObuTaP8q6KjkTeRI43wls9sxuFis5382FTiB_nNmzV2fBP0wQRznYqFPiyoGfoqSCV5TWqeIJ_baH3vspuFSJmRJ5VVdsFvz6Pvq__t9-KwHlDtDBxxjASG1HNVo_J2N7mRM5N4bca4xkd7Fn9yb9P4tnqcS71w
CitedBy_id crossref_primary_10_1016_j_phrs_2024_107123
crossref_primary_10_1016_j_tips_2024_04_009
crossref_primary_10_1002_mog2_70019
crossref_primary_10_3390_cimb46070447
crossref_primary_10_3389_fonc_2023_1163504
crossref_primary_10_3390_pharmaceutics16070890
crossref_primary_10_1016_j_biopha_2023_115079
crossref_primary_10_3390_cancers15061909
crossref_primary_10_3390_jpm14070752
crossref_primary_10_1158_0008_5472_CAN_24_0274
crossref_primary_10_1038_s41598_025_10412_4
crossref_primary_10_1096_fj_202301209R
crossref_primary_10_3389_fimmu_2023_1332057
crossref_primary_10_1038_s41401_024_01451_0
crossref_primary_10_1186_s43556_024_00239_2
crossref_primary_10_1016_j_medidd_2025_100210
crossref_primary_10_3389_fimmu_2023_1094764
crossref_primary_10_3390_genes14051014
crossref_primary_10_3892_ol_2024_14827
crossref_primary_10_3390_ph18071077
crossref_primary_10_1038_s41571_025_01003_3
crossref_primary_10_1016_j_jtocrr_2025_100832
crossref_primary_10_1097_CAD_0000000000001707
crossref_primary_10_3390_cancers16213563
crossref_primary_10_3390_cancers16132490
crossref_primary_10_3389_fonc_2023_1116809
crossref_primary_10_12701_jyms_2025_42_36
crossref_primary_10_3389_fimmu_2024_1484915
crossref_primary_10_3390_ijms26136157
crossref_primary_10_1016_j_annonc_2024_10_006
crossref_primary_10_1097_MD_0000000000038277
crossref_primary_10_1007_s00441_024_03942_2
crossref_primary_10_1016_j_apsb_2025_06_002
crossref_primary_10_1186_s12964_024_01876_4
crossref_primary_10_1016_j_tice_2024_102410
crossref_primary_10_1038_s41392_024_01899_w
crossref_primary_10_1080_14712598_2025_2507833
crossref_primary_10_1016_j_heliyon_2024_e27152
crossref_primary_10_1186_s12944_025_02559_w
crossref_primary_10_1016_j_drup_2025_101237
crossref_primary_10_1186_s12957_023_03203_6
crossref_primary_10_1038_s43018_024_00806_0
crossref_primary_10_3390_jfb14090466
Cites_doi 10.1016/j.cell.2008.09.050
10.1126/science.1073096
10.1016/j.phrs.2013.11.002
10.1016/j.ejmech.2021.113328
10.1038/s41568-021-00365-x
10.1016/j.jtho.2019.04.014
10.1038/s41588-020-00749-z
10.1038/nrc2088
10.2147/OTT.S97644
10.1016/j.ejmech.2021.113786
10.1016/S1470-2045(12)70087-6
10.1200/JCO.2012.45.0981
10.1158/2159-8290.CD-21-1059
10.1016/j.cell.2018.06.025
10.1038/nature08622
10.1038/nature24297
10.3322/caac.21660
10.1038/nm.3854
10.1038/nrc.2017.87
10.1016/j.cell.2020.10.027
10.1038/s41467-018-05626-2
10.1016/j.cell.2012.02.063
10.1056/NEJMoa1413654
10.1001/jamaoncol.2018.2969
10.1016/j.stem.2016.11.003
10.1093/annonc/mdy424.064
10.1038/s43018-021-00195-8
10.1038/s41587-021-01005-3
10.1038/s41596-019-0290-z
10.1016/S1470-2045(19)30504-2
10.1038/nm.4040
10.1016/j.ejmech.2020.112061
10.1093/annonc/mdy424.063
10.1016/j.cell.2020.11.018
10.1038/ncomms3467
10.1158/1078-0432.CCR-15-0560
10.1056/NEJMoa1612674
10.1038/nature22794
10.1038/s41591-018-0264-7
10.1158/2159-8290.CD-18-1022
10.1038/s43018-022-00351-8
10.2147/OTT.S188612
10.1016/j.annonc.2021.08.1966
10.1016/j.cell.2019.11.031
10.1126/science.1099314
10.1038/s41388-018-0454-2
10.1038/ng.2330
10.1097/JTO.0000000000000033
10.1200/JCO.2014.58.1736
10.1016/j.cell.2010.02.027
10.1016/j.cell.2020.07.017
10.1158/1078-0432.CCR-12-2246
10.1038/nrmicro.2017.42
10.1126/science.aaw3381
10.1158/1535-7163.TARG-21-P230
10.1016/j.ccr.2009.11.022
10.1158/2159-8290.CD-20-1588
10.1016/j.jtho.2016.03.012
10.1056/NEJMoa040938
10.1016/j.molcel.2016.06.017
10.1038/nrc.2017.84
10.1002/ijc.30691
10.1158/1078-0432.CCR-17-2310
10.1158/2159-8290.CD-12-0103
10.3390/cells11132078
10.1097/JTO.0b013e3182781e35
10.1016/j.jtho.2021.07.017
10.1056/NEJMoa1411817
10.1016/S1470-2045(11)70393-X
10.1101/2021.12.08.471833
10.1038/ncomms10690
10.1016/j.critrevonc.2014.11.005
10.1016/j.ejmech.2020.112781
10.1158/1078-0432.CCR-13-1854
10.1038/s41467-018-08074-0
10.1016/j.ccell.2021.07.006
10.1016/S1470-2045(09)70364-X
10.1158/2159-8290.CD-22-0111
10.1056/NEJMoa1913662
10.1158/0008-5472.CAN-13-3456
10.3390/cancers13184705
10.1136/esmoopen-2016-000060
10.1016/j.ccell.2017.07.002
10.1073/pnas.1712064115
10.1038/s41586-018-0744-4
10.1038/s41592-018-0185-x
10.1038/nature17960
10.1016/j.ccell.2020.12.002
10.1016/j.cell.2013.08.031
10.1016/S2213-2600(17)30480-0
10.1038/nature25183
10.1093/annonc/mdv276
10.1126/science.1160809
10.1038/s41591-021-01450-2
10.1038/s41568-020-00302-4
10.1158/2159-8290.CD-15-0063
10.1038/s41586-021-03796-6
10.1038/nm.3841
10.1093/annonc/mdv128.05
10.1038/nrg.2016.98
10.1371/journal.pmed.0020073
10.1073/pnas.0709662105
10.1016/j.ccell.2019.12.006
10.1016/j.jtho.2020.09.001
10.1136/tc.2007.022582
10.1158/1538-7445.AM2019-1320
10.1056/NEJMoa1713137
10.1038/nature13121
10.3390/cells9122601
10.1158/1535-7163.MCT-21-0835
10.1038/nrc3775
ContentType Journal Article
Copyright 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Distributed under a Creative Commons Attribution 4.0 International License
2023 by the authors. 2023
Copyright_xml – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
NPM
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
1XC
5PM
DOI 10.3390/cancers15020504
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Hyper Article en Ligne (HAL)
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC9856371
oai:HAL:hal-05043716v1
36672453
10_3390_cancers15020504
Genre Journal Article
Review
GrantInformation_xml – fundername: Fondation pour la Recherche Médicale
  grantid: FDT202001010860
– fundername: French National Cancer Institute
  grantid: PLBIO 2017-157
– fundername: Nabatieh Municipal Council (Lebanon)
– fundername: Conseil Régional de Normandie
– fundername: FEDER program of the European Union
– fundername: Institut National du Cancer
  grantid: PLBIO 2017-159
– fundername: Université de Rouen Normandie
– fundername: Fondation pour la Recherche Médicale
  grantid: FDT 202001010860
– fundername: Institut National de la Santé et de la Recherche Médicale (INSERM)
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
RPM
TUS
3V.
GROUPED_DOAJ
NPM
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
1XC
5PM
ID FETCH-LOGICAL-c521t-d2903e6bb4b7dfcfb6eee69baff29e9e33e7d5d734e544af1357502eef1b80d3
IEDL.DBID M7P
ISICitedReferencesCount 55
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000916934200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2072-6694
IngestDate Tue Nov 04 02:06:39 EST 2025
Tue Oct 14 20:41:04 EDT 2025
Thu Oct 02 09:54:06 EDT 2025
Fri Jul 25 11:56:55 EDT 2025
Thu Jan 02 22:53:12 EST 2025
Tue Nov 18 20:58:01 EST 2025
Sat Nov 29 07:21:14 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords non-small cell lung cancer
targeted therapy
EGFR-TKI
drug resistance
drug tolerant persister cells
cellular barcoding
lung cancer
preclinical models
targeted therapies
transcriptomic
hepatocyte growth factor
tyrosine kinase receptor
Language English
License Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c521t-d2903e6bb4b7dfcfb6eee69baff29e9e33e7d5d734e544af1357502eef1b80d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMCID: PMC9856371
ORCID 0000-0001-8231-3032
0000-0003-4811-0818
OpenAccessLink https://www.proquest.com/docview/2767189831?pq-origsite=%requestingapplication%
PMID 36672453
PQID 2767189831
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9856371
hal_primary_oai_HAL_hal_05043716v1
proquest_miscellaneous_2768229767
proquest_journals_2767189831
pubmed_primary_36672453
crossref_citationtrail_10_3390_cancers15020504
crossref_primary_10_3390_cancers15020504
PublicationCentury 2000
PublicationDate 20230113
PublicationDateYYYYMMDD 2023-01-13
PublicationDate_xml – month: 1
  year: 2023
  text: 20230113
  day: 13
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Cantley (ref_93) 2009; 324
Herbst (ref_3) 2018; 553
ref_99
Rehman (ref_108) 2021; 184
Kebschull (ref_110) 2018; 15
Burslem (ref_61) 2020; 181
Tricker (ref_82) 2015; 5
Oxnard (ref_44) 2018; 4
Kate (ref_19) 2019; 10
Ramalingam (ref_40) 2020; 382
ref_27
Liau (ref_78) 2017; 20
Yang (ref_33) 2017; 140
Biddy (ref_111) 2018; 564
Pisco (ref_100) 2013; 4
Rekhtman (ref_7) 2019; 14
Du (ref_66) 2022; 21
Guernet (ref_114) 2016; 63
Soria (ref_41) 2018; 378
Weinreb (ref_112) 2020; 367
Sun (ref_77) 2014; 508
Haspinger (ref_32) 2015; 94
ref_79
Guler (ref_80) 2017; 32
Arasada (ref_90) 2018; 9
Davidson (ref_6) 2013; 5
Rotow (ref_11) 2017; 17
Fisher (ref_72) 2017; 15
Mitsudomi (ref_22) 2010; 11
Shaffer (ref_97) 2017; 546
To (ref_56) 2022; 3
Weng (ref_54) 2019; 38
Weinstein (ref_10) 2002; 297
Lin (ref_51) 2018; 6
Bramlett (ref_109) 2020; 15
Shen (ref_71) 2020; 183
Raha (ref_95) 2014; 74
Sung (ref_1) 2021; 71
Kobayashi (ref_17) 2013; 8
Zhou (ref_34) 2009; 462
Tsao (ref_12) 2016; 11
Katakami (ref_30) 2013; 31
Liu (ref_60) 2019; 79
Hanahan (ref_92) 2022; 12
ref_85
Hangauer (ref_96) 2017; 551
Noronha (ref_86) 2022; 12
Ercan (ref_81) 2012; 2
Papadimitrakopoulou (ref_46) 2018; 29
Russo (ref_73) 2021; 11
Wang (ref_9) 2021; 27
Sequist (ref_36) 2015; 372
Zhang (ref_50) 2018; 12
Ahn (ref_38) 2015; 26
Yu (ref_28) 2013; 19
Chen (ref_4) 2014; 14
Touil (ref_76) 2014; 20
Yun (ref_29) 2008; 105
Oren (ref_105) 2021; 596
Sharma (ref_20) 2007; 7
Vasconcelos (ref_25) 2020; 1
Shan (ref_18) 2012; 149
Bhang (ref_67) 2015; 21
Rambow (ref_106) 2018; 174
Ahn (ref_42) 2019; 20
Hata (ref_68) 2016; 22
Mok (ref_39) 2017; 376
Morgillo (ref_26) 2016; 1
Dhimolea (ref_107) 2021; 39
Gazdar (ref_2) 2017; 17
Ferlenghi (ref_57) 2021; 225
Maynard (ref_91) 2020; 182
Qu (ref_63) 2021; 218
Lee (ref_21) 2015; 33
Paez (ref_15) 2004; 304
Sharma (ref_74) 2010; 141
Lim (ref_59) 2021; 32
Ramirez (ref_75) 2016; 7
Marine (ref_70) 2020; 20
Zhang (ref_84) 2012; 44
Roskoski (ref_13) 2014; 79
Shah (ref_87) 2019; 25
Spigel (ref_58) 2021; 20
Zhao (ref_65) 2020; 208
Miller (ref_31) 2012; 13
Tanaka (ref_88) 2021; 39
Chang (ref_113) 2022; 40
Passaro (ref_52) 2021; 2
Turke (ref_69) 2010; 17
Taniguchi (ref_83) 2019; 10
Thress (ref_45) 2015; 21
Yang (ref_49) 2018; 24
Ramalingam (ref_48) 2018; 29
Shi (ref_14) 2014; 9
Jia (ref_55) 2016; 534
Su (ref_101) 2017; 114
Yang (ref_43) 2020; 15
Pauklin (ref_104) 2013; 155
Niederst (ref_47) 2015; 21
Kenfield (ref_5) 2008; 17
Mikubo (ref_94) 2021; 16
Zhang (ref_64) 2020; 189
Lynch (ref_16) 2004; 350
Dale (ref_62) 2021; 21
Yang (ref_35) 2015; 372
Piotrowska (ref_53) 2018; 8
Caparello (ref_37) 2016; 9
Torre (ref_98) 2021; 53
Zhou (ref_23) 2015; 26
Rosell (ref_24) 2012; 13
Raj (ref_103) 2008; 135
ref_8
Kurppa (ref_89) 2020; 37
Moris (ref_102) 2016; 17
References_xml – volume: 135
  start-page: 216
  year: 2008
  ident: ref_103
  article-title: Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences
  publication-title: Cell
  doi: 10.1016/j.cell.2008.09.050
– volume: 297
  start-page: 63
  year: 2002
  ident: ref_10
  article-title: Addiction to Oncogenes—The Achilles Heal of Cancer
  publication-title: Science
  doi: 10.1126/science.1073096
– volume: 79
  start-page: 34
  year: 2014
  ident: ref_13
  article-title: The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2013.11.002
– volume: 218
  start-page: 113328
  year: 2021
  ident: ref_63
  article-title: Effective Degradation of EGFRL858R+T790M Mutant Proteins by CRBN-Based PROTACs through Both Proteosome and Autophagy/Lysosome Degradation Systems
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2021.113328
– volume: 21
  start-page: 638
  year: 2021
  ident: ref_62
  article-title: Advancing Targeted Protein Degradation for Cancer Therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-021-00365-x
– volume: 14
  start-page: 1125
  year: 2019
  ident: ref_7
  article-title: Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.04.014
– volume: 53
  start-page: 76
  year: 2021
  ident: ref_98
  article-title: Genetic Screening for Single-Cell Variability Modulators Driving Therapy Resistance
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-00749-z
– volume: 7
  start-page: 169
  year: 2007
  ident: ref_20
  article-title: Epidermal Growth Factor Receptor Mutations in Lung Cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2088
– volume: 9
  start-page: 6065
  year: 2016
  ident: ref_37
  article-title: New Developments in the Management of Non-Small-Cell Lung Cancer, Focus on Rociletinib: What Went Wrong?
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S97644
– volume: 225
  start-page: 113786
  year: 2021
  ident: ref_57
  article-title: A Sulfonyl Fluoride Derivative Inhibits EGFRL858R/T790M/C797S by Covalent Modification of the Catalytic Lysine
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2021.113786
– volume: 13
  start-page: 528
  year: 2012
  ident: ref_31
  article-title: Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small-Cell Lung Cancer after Failure of Erlotinib, Gefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(12)70087-6
– volume: 31
  start-page: 3335
  year: 2013
  ident: ref_30
  article-title: LUX-Lung 4: A Phase II Trial of Afatinib in Patients with Advanced Non-Small-Cell Lung Cancer Who Progressed during Prior Treatment with Erlotinib, Gefitinib, or Both
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.45.0981
– volume: 1
  start-page: 100051
  year: 2020
  ident: ref_25
  article-title: EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  publication-title: JTO Clin. Res. Rep.
– volume: 12
  start-page: 31
  year: 2022
  ident: ref_92
  article-title: Hallmarks of Cancer: New Dimensions
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-21-1059
– volume: 174
  start-page: 843
  year: 2018
  ident: ref_106
  article-title: Toward Minimal Residual Disease-Directed Therapy in Melanoma
  publication-title: Cell
  doi: 10.1016/j.cell.2018.06.025
– volume: 462
  start-page: 1070
  year: 2009
  ident: ref_34
  article-title: Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790M
  publication-title: Nature
  doi: 10.1038/nature08622
– volume: 551
  start-page: 247
  year: 2017
  ident: ref_96
  article-title: Drug-Tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition
  publication-title: Nature
  doi: 10.1038/nature24297
– volume: 71
  start-page: 209
  year: 2021
  ident: ref_1
  article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 21
  start-page: 560
  year: 2015
  ident: ref_45
  article-title: Acquired EGFR C797S Mediates Resistance to AZD9291 in Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M
  publication-title: Nat. Med.
  doi: 10.1038/nm.3854
– volume: 17
  start-page: 725
  year: 2017
  ident: ref_2
  article-title: Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.87
– volume: 183
  start-page: 860
  year: 2020
  ident: ref_71
  article-title: Persistent Cancer Cells: The Deadly Survivors
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.027
– volume: 9
  start-page: 3198
  year: 2018
  ident: ref_90
  article-title: Notch3-Dependent β-Catenin Signaling Mediates EGFR TKI Drug Persistence in EGFR Mutant NSCLC
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05626-2
– volume: 149
  start-page: 860
  year: 2012
  ident: ref_18
  article-title: Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.063
– volume: 372
  start-page: 1700
  year: 2015
  ident: ref_36
  article-title: Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1413654
– volume: 4
  start-page: 1527
  year: 2018
  ident: ref_44
  article-title: Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.2969
– volume: 20
  start-page: 233
  year: 2017
  ident: ref_78
  article-title: Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2016.11.003
– volume: 29
  start-page: viii741
  year: 2018
  ident: ref_46
  article-title: Analysis of Resistance Mechanisms to Osimertinib in Patients with EGFR T790M Advanced NSCLC from the AURA3 Study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy424.064
– volume: 2
  start-page: 377
  year: 2021
  ident: ref_52
  article-title: Overcoming Therapy Resistance in EGFR-Mutant Lung Cancer
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00195-8
– volume: 40
  start-page: 86
  year: 2022
  ident: ref_113
  article-title: Identifying Transcriptional Programs Underlying Cancer Drug Response with TraCe-Seq
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-021-01005-3
– volume: 15
  start-page: 1436
  year: 2020
  ident: ref_109
  article-title: Clonal Tracking Using Embedded Viral Barcoding and High-Throughput Sequencing
  publication-title: Nat. Protoc.
  doi: 10.1038/s41596-019-0290-z
– volume: 20
  start-page: 1681
  year: 2019
  ident: ref_42
  article-title: Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Results from the Dose Escalation and Dose Expansion Parts of a First-in-Human, Open-Label, Multicentre, Phase 1–2 Study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30504-2
– volume: 22
  start-page: 262
  year: 2016
  ident: ref_68
  article-title: Tumor Cells Can Follow Distinct Evolutionary Paths to Become Resistant to Epidermal Growth Factor Receptor Inhibition
  publication-title: Nat. Med.
  doi: 10.1038/nm.4040
– volume: 189
  start-page: 112061
  year: 2020
  ident: ref_64
  article-title: Discovery of Potent Epidermal Growth Factor Receptor (EGFR) Degraders by Proteolysis Targeting Chimera (PROTAC)
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2020.112061
– volume: 29
  start-page: viii740
  year: 2018
  ident: ref_48
  article-title: Mechanisms of Acquired Resistance to First-Line Osimertinib: Preliminary Data from the Phase III FLAURA Study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy424.063
– volume: 184
  start-page: 226
  year: 2021
  ident: ref_108
  article-title: Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2020.11.018
– volume: 4
  start-page: 2467
  year: 2013
  ident: ref_100
  article-title: Non-Darwinian Dynamics in Therapy-Induced Cancer Drug Resistance
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3467
– volume: 21
  start-page: 3924
  year: 2015
  ident: ref_47
  article-title: The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-0560
– volume: 376
  start-page: 629
  year: 2017
  ident: ref_39
  article-title: Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1612674
– volume: 546
  start-page: 431
  year: 2017
  ident: ref_97
  article-title: Rare Cell Variability and Drug-Induced Reprogramming as a Mode of Cancer Drug Resistance
  publication-title: Nature
  doi: 10.1038/nature22794
– volume: 25
  start-page: 111
  year: 2019
  ident: ref_87
  article-title: Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung Cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0264-7
– volume: 8
  start-page: 1529
  year: 2018
  ident: ref_53
  article-title: Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1022
– volume: 3
  start-page: 402
  year: 2022
  ident: ref_56
  article-title: An Allosteric Inhibitor against the Therapy-Resistant Mutant Forms of EGFR in Non-Small Cell Lung Cancer
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00351-8
– volume: 12
  start-page: 51
  year: 2018
  ident: ref_50
  article-title: Newly Emergent Acquired EGFR Exon 18 G724S Mutation after Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-Cell Lung Cancer: A Case Report
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S188612
– volume: 32
  start-page: S1035
  year: 2021
  ident: ref_59
  article-title: 1365TiP A Phase I/II, Open-Label Study of BBT-176, a Triple Mutation Targeting EGFR TKI, in Patients with NSCLC Who Progressed after Prior EGFR TKI Therapy
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.08.1966
– volume: 181
  start-page: 102
  year: 2020
  ident: ref_61
  article-title: Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
  publication-title: Cell
  doi: 10.1016/j.cell.2019.11.031
– volume: 304
  start-page: 1497
  year: 2004
  ident: ref_15
  article-title: EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  publication-title: Science
  doi: 10.1126/science.1099314
– volume: 38
  start-page: 455
  year: 2019
  ident: ref_54
  article-title: Epithelial-Mesenchymal Transition (EMT) beyond EGFR Mutations per Se Is a Common Mechanism for Acquired Resistance to EGFR TKI
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0454-2
– volume: 44
  start-page: 852
  year: 2012
  ident: ref_84
  article-title: Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
  publication-title: Nat. Genet.
  doi: 10.1038/ng.2330
– volume: 9
  start-page: 154
  year: 2014
  ident: ref_14
  article-title: A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0000000000000033
– volume: 33
  start-page: 1958
  year: 2015
  ident: ref_21
  article-title: Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.58.1736
– volume: 141
  start-page: 69
  year: 2010
  ident: ref_74
  article-title: A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
  publication-title: Cell
  doi: 10.1016/j.cell.2010.02.027
– volume: 182
  start-page: 1232
  year: 2020
  ident: ref_91
  article-title: Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
  publication-title: Cell
  doi: 10.1016/j.cell.2020.07.017
– volume: 19
  start-page: 2240
  year: 2013
  ident: ref_28
  article-title: Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI Therapy in 155 Patients with EGFR Mutant Lung Cancers
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2246
– volume: 15
  start-page: 453
  year: 2017
  ident: ref_72
  article-title: Persistent Bacterial Infections and Persister Cells
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro.2017.42
– volume: 367
  start-page: eaaw3381
  year: 2020
  ident: ref_112
  article-title: Lineage Tracing on Transcriptional Landscapes Links State to Fate during Differentiation
  publication-title: Science
  doi: 10.1126/science.aaw3381
– volume: 20
  start-page: P230
  year: 2021
  ident: ref_58
  article-title: Abstract P230: A Phase 1/2 Study of BLU-945, a Highly Potent and Selective Inhibitor of Epidermal Growth Factor Receptor (EGFR) Resistance Mutations, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.TARG-21-P230
– volume: 17
  start-page: 77
  year: 2010
  ident: ref_69
  article-title: Pre-Existence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.11.022
– volume: 11
  start-page: 1886
  year: 2021
  ident: ref_73
  article-title: Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-1588
– volume: 11
  start-page: 613
  year: 2016
  ident: ref_12
  article-title: Scientific Advances in Lung Cancer 2015
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2016.03.012
– volume: 350
  start-page: 2129
  year: 2004
  ident: ref_16
  article-title: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa040938
– volume: 63
  start-page: 526
  year: 2016
  ident: ref_114
  article-title: CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2016.06.017
– volume: 17
  start-page: 637
  year: 2017
  ident: ref_11
  article-title: Understanding and Targeting Resistance Mechanisms in NSCLC
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.84
– volume: 140
  start-page: 2805
  year: 2017
  ident: ref_33
  article-title: Comparison of Gefitinib, Erlotinib and Afatinib in Non-Small Cell Lung Cancer: A Meta-Analysis
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.30691
– volume: 24
  start-page: 3097
  year: 2018
  ident: ref_49
  article-title: Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-2310
– volume: 2
  start-page: 934
  year: 2012
  ident: ref_81
  article-title: Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0103
– ident: ref_85
  doi: 10.3390/cells11132078
– volume: 8
  start-page: 45
  year: 2013
  ident: ref_17
  article-title: Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3182781e35
– volume: 16
  start-page: 1798
  year: 2021
  ident: ref_94
  article-title: Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2021.07.017
– volume: 372
  start-page: 1689
  year: 2015
  ident: ref_35
  article-title: AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1411817
– volume: 13
  start-page: 239
  year: 2012
  ident: ref_24
  article-title: Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70393-X
– ident: ref_99
  doi: 10.1101/2021.12.08.471833
– volume: 7
  start-page: 10690
  year: 2016
  ident: ref_75
  article-title: Diverse Drug-Resistance Mechanisms Can Emerge from Drug-Tolerant Cancer Persister Cells
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10690
– volume: 94
  start-page: 213
  year: 2015
  ident: ref_32
  article-title: Is There Evidence for Different Effects among EGFR-TKIs? Systematic Review and Meta-Analysis of EGFR Tyrosine Kinase Inhibitors (TKIs) versus Chemotherapy as First-Line Treatment for Patients Harboring EGFR Mutations
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2014.11.005
– volume: 208
  start-page: 112781
  year: 2020
  ident: ref_65
  article-title: Discovery of Potent Small Molecule PROTACs Targeting Mutant EGFR
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2020.112781
– volume: 20
  start-page: 837
  year: 2014
  ident: ref_76
  article-title: Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1854
– volume: 10
  start-page: 259
  year: 2019
  ident: ref_83
  article-title: AXL Confers Intrinsic Resistance to Osimertinib and Advances the Emergence of Tolerant Cells
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-08074-0
– volume: 39
  start-page: 1245
  year: 2021
  ident: ref_88
  article-title: Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-Mediated Apoptosis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.07.006
– volume: 11
  start-page: 121
  year: 2010
  ident: ref_22
  article-title: Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(09)70364-X
– volume: 12
  start-page: 2666
  year: 2022
  ident: ref_86
  article-title: AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-22-0111
– volume: 382
  start-page: 41
  year: 2020
  ident: ref_40
  article-title: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1913662
– volume: 74
  start-page: 3579
  year: 2014
  ident: ref_95
  article-title: The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-3456
– ident: ref_8
  doi: 10.3390/cancers13184705
– volume: 1
  start-page: e000060
  year: 2016
  ident: ref_26
  article-title: Mechanisms of Resistance to EGFR-Targeted Drugs: Lung Cancer
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2016-000060
– volume: 32
  start-page: 221
  year: 2017
  ident: ref_80
  article-title: Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.07.002
– volume: 114
  start-page: 13679
  year: 2017
  ident: ref_101
  article-title: Single-Cell Analysis Resolves the Cell State Transition and Signaling Dynamics Associated with Melanoma Drug-Induced Resistance
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1712064115
– volume: 564
  start-page: 219
  year: 2018
  ident: ref_111
  article-title: Single-Cell Mapping of Lineage and Identity in Direct Reprogramming
  publication-title: Nature
  doi: 10.1038/s41586-018-0744-4
– volume: 15
  start-page: 871
  year: 2018
  ident: ref_110
  article-title: Cellular Barcoding: Lineage Tracing, Screening and Beyond
  publication-title: Nat. Methods
  doi: 10.1038/s41592-018-0185-x
– volume: 534
  start-page: 129
  year: 2016
  ident: ref_55
  article-title: Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors
  publication-title: Nature
  doi: 10.1038/nature17960
– volume: 39
  start-page: 240
  year: 2021
  ident: ref_107
  article-title: An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.12.002
– volume: 155
  start-page: 135
  year: 2013
  ident: ref_104
  article-title: The Cell-Cycle State of Stem Cells Determines Cell Fate Propensity
  publication-title: Cell
  doi: 10.1016/j.cell.2013.08.031
– volume: 6
  start-page: 107
  year: 2018
  ident: ref_51
  article-title: Outcomes in Patients with Non-Small-Cell Lung Cancer and Acquired Thr790Met Mutation Treated with Osimertinib: A Genomic Study
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(17)30480-0
– volume: 553
  start-page: 446
  year: 2018
  ident: ref_3
  article-title: The Biology and Management of Non-Small Cell Lung Cancer
  publication-title: Nature
  doi: 10.1038/nature25183
– volume: 26
  start-page: 1877
  year: 2015
  ident: ref_23
  article-title: Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib versus Chemotherapy as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802)
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv276
– volume: 324
  start-page: 1029
  year: 2009
  ident: ref_93
  article-title: Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
  publication-title: Science
  doi: 10.1126/science.1160809
– volume: 27
  start-page: 1345
  year: 2021
  ident: ref_9
  article-title: Toward Personalized Treatment Approaches for Non-Small-Cell Lung Cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01450-2
– volume: 20
  start-page: 743
  year: 2020
  ident: ref_70
  article-title: Non-Genetic Mechanisms of Therapeutic Resistance in Cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-00302-4
– volume: 5
  start-page: 960
  year: 2015
  ident: ref_82
  article-title: Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-15-0063
– volume: 596
  start-page: 576
  year: 2021
  ident: ref_105
  article-title: Cycling Cancer Persister Cells Arise from Lineages with Distinct Programs
  publication-title: Nature
  doi: 10.1038/s41586-021-03796-6
– volume: 21
  start-page: 440
  year: 2015
  ident: ref_67
  article-title: Studying Clonal Dynamics in Response to Cancer Therapy Using High-Complexity Barcoding
  publication-title: Nat. Med.
  doi: 10.1038/nm.3841
– volume: 26
  start-page: i57
  year: 2015
  ident: ref_38
  article-title: A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc—Updated Progression Free Survival and Duration of Response Data
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv128.05
– volume: 17
  start-page: 693
  year: 2016
  ident: ref_102
  article-title: Transition States and Cell Fate Decisions in Epigenetic Landscapes
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg.2016.98
– ident: ref_27
  doi: 10.1371/journal.pmed.0020073
– volume: 105
  start-page: 2070
  year: 2008
  ident: ref_29
  article-title: The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0709662105
– volume: 37
  start-page: 104
  year: 2020
  ident: ref_89
  article-title: Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.12.006
– volume: 15
  start-page: 1907
  year: 2020
  ident: ref_43
  article-title: Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-Label, Phase 1 Trial
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2020.09.001
– volume: 5
  start-page: S463
  year: 2013
  ident: ref_6
  article-title: The Pivotal Role of Pathology in the Management of Lung Cancer
  publication-title: J. Thorac. Dis.
– volume: 17
  start-page: 198
  year: 2008
  ident: ref_5
  article-title: Comparison of Aspects of Smoking Among Four Histologic Types of Lung Cancer
  publication-title: Tob. Control
  doi: 10.1136/tc.2007.022582
– volume: 79
  start-page: 1320
  year: 2019
  ident: ref_60
  article-title: Abstract 1320: Preclinical Evaluation of TQB3804, a Potent EGFR C797S Inhibitor
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2019-1320
– volume: 10
  start-page: 1
  year: 2019
  ident: ref_19
  article-title: Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients: A Single Center Retrospective Analysis
  publication-title: Lung Cancer
– volume: 378
  start-page: 113
  year: 2018
  ident: ref_41
  article-title: Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1713137
– volume: 508
  start-page: 118
  year: 2014
  ident: ref_77
  article-title: Reversible and Adaptive Resistance to BRAF(V600E) Inhibition in Melanoma
  publication-title: Nature
  doi: 10.1038/nature13121
– ident: ref_79
  doi: 10.3390/cells9122601
– volume: 21
  start-page: 1060
  year: 2022
  ident: ref_66
  article-title: HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC That Overcomes Osimertinib-Resistant EGFR Triple Mutations
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-21-0835
– volume: 14
  start-page: 535
  year: 2014
  ident: ref_4
  article-title: Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3775
SSID ssj0000331767
Score 2.5074615
SecondaryResourceType review_article
Snippet Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase...
Simple SummaryLung cancer is the major cause of cancer-related deaths worldwide. The development of targeted therapies has dramatically improved the outcome of...
SourceID pubmedcentral
hal
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 504
SubjectTerms Animals
Antitumor agents
Cancer therapies
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Clinical trials
Drug tolerance
Epidermal growth factor
Epidermal growth factor receptors
Exons
Growth factors
Hepatocyte Growth Factor
Humans
Kinases
Life Sciences
Ligands
Lung cancer
Lung Neoplasms
Metastasis
Mice
Mutation
Non-small cell lung carcinoma
Protein Kinase Inhibitors
Protein-tyrosine kinase
Proto-Oncogene Proteins c-met
Response rates
Review
Small cell lung carcinoma
Tumors
Title Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/36672453
https://www.proquest.com/docview/2767189831
https://www.proquest.com/docview/2768229767
https://hal.science/hal-05043716
https://pubmed.ncbi.nlm.nih.gov/PMC9856371
Volume 15
WOSCitedRecordID wos000916934200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M~E
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M7P
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M2O
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED_RDSFexucgMCqDeOAlLLGTOHlCpWoZ0lqikofyFNmxrVXqktF0-_t3TtJAh-CFl0i2L8nFZ5_P58vvAN5LozgzMnA9bqQbKENd4bPC9QsmfSEirWPTJJvg83m8XCZp53Cru7DKnU5sFLWqCusjP6U8QjWaxMz_dPXTtVmj7Olql0JjAIcWJYE2oXtp72PxGK6OEW8RfRju7k8L25WbGq0g6oVdcrbdYjS4sKGQf9qZd8Mlf1t_po_-l_PHcNRZnmTUDpUncE-XT-HBrDtbfwZmpu1fwKv6siaVIaPCxghrRRa6tjYmfhERpSJZtdabprStyOTLdEGyJpgcKbMWoYCsSjKvSvf7pVivyVjj5RxVChk3vfIcsukkG5-5XRYGt7DJDlxFE4_pSMpAcmUKI1F-OkqkMIYmOtGMaa5ClHigwyAQxmdoAXpUa-PL2FPsGA7KqtQvgcQ8kQb3Oyrx4qAwgZCSMx4ozxNxiI9y4ONOGnnRIZTbRBnrHHcqVnz5HfE58KG_4aoF5_g76TsUb09lQbXPRue5rbPNDLeNN74DJzsJ5t1UrvNf4nPgbd-Mk9CerIhSV9cNjQXOR0oHXrSDpX8ViyJOg5A5wPeG0R4v-y3l6qIB-k7iMELOXv2brdfwkKLlZf1CPjuBg-3mWr-B-8XNdlVvhjDgy3gIh58n83SBpRn9NmxmCdalX2fpj1tDuB1h
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED9tHQJe-GYLDDAIJF7CktiJkweEqrLSam1VjTyMpyiOba1Sl4ymG-KP4n_knC_oELztgZdIiS_J2f75fGef7wBeCy051YLZDtfCZlJ7durSzHYzKtw0DZQKdZVsgs9m4clJNN-CH-1ZGONW2crESlDLIjNr5AceD1CMRiF1P5x_tU3WKLO72qbQqGFxpL5_Q5OtfD_-iP37xvOGh_FgZDdZBezMBO-3pRc5VAVCMMGlzrRAflQQiVRrL1KRolRx6WMNmPIZS7VLUaNxPKW0K0JHUvzsNuwwg_Ue7MzH0_mXblHHoTgdB7wOIURp5Bxkpu9WJapdnuM32eDa2W_71Phe_qnYXvXP_G3CG979z5rqHtxpNGvSr4fCfdhS-QO4OW18Bx6CnipzynlRnpWk0KSfGR9oJcmxKo0OjQ1I0lySuFiqVXW3Lsjhp-ExiStneaSM6wgMZJGTWZHbn8_S5ZIMFF4mKDLJoOqERxBfRyUfQy8vcrUHJOSR0GjPycgJWaZZKgSnnEnHSUMfP2XBu7bzk6yJwG4SgSwTtMQMWpIraLHgbffCeR185O-krxBNHZUJGj7qTxLzzBRTNIsvXQv2W8Akjagqk19oseBlV4xCxuwcpbkqLioakxgAKS3YrbHZ_YoGAfeYTy3gG6jd4GWzJF-cVoHMo9APkLMn_2brBdwaxdNJMhnPjp7CbQ-1TLMG5tJ96K1XF-oZ3Mgu14ty9bwZjgSSa0b1T-dYeT4
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED9tHZp44fsjMMAgkHgJTWwnTh4QqrqVVWuravRhe4ri2NYqdclouiH-NP47zvkodAje9sBLpMSX5Gz_fL6zz3cAb6VRghnJXU8Y6XJlqJv6LHP9jEk_TUOtI1MlmxCTSXRyEk-34Ed7Fsa6VbYysRLUqsjsGnmXihDFaBwxv2sat4jp_uDTxVfXZpCyO61tOo0aIkf6-zc038qPw33s63eUDg5m_UO3yTDgZjaQv6to7DEdSsmlUCYzEnnTYSxTY2isY82YFirA2nAdcJ4an6F241GtjS8jTzH87DbsoEbOaQd2psPx9HS9wOMxnJpDUYcTYiz2upntx2WJKhj1giYzXDsTbp9ZP8w_ldzrvpq_TX6Du_9xs92DO43GTXr1ELkPWzp_ALvjxqfgIZixtqef5-V5SQpDepn1jdaKHOvS6tbYmCTNFZkVC72s7lYFOfg8OCazyokeKWd1ZAYyz8mkyN0v5-liQfoaLyMUpaRfdcgjmN1EJR9DJy9y_RRIJGJp0M5TsRfxzPBUSsEEV56XRgF-yoEPLRCSrInMbhOELBK00CxykmvIceD9-oWLOijJ30nfILLWVDaY-GFvlNhntpihuXzlO7DXgidpRFiZ_EKOA6_XxSh87I5SmuvisqKxCQOQ0oEnNU7Xv2JhKCgPmANiA8EbvGyW5POzKsB5HAUhcvbs32y9gl2EcjIaTo6ew22KyqddGvPZHnRWy0v9Am5lV6t5uXzZjEwCyQ2D-idJ5YH-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanisms+of+Acquired+Resistance+and+Tolerance+to+EGFR+Targeted+Therapy+in+Non-Small+Cell+Lung+Cancer&rft.jtitle=Cancers&rft.au=Chhouri%2C+Houssein&rft.au=Alexandre%2C+David&rft.au=Grumolato%2C+Luca&rft.date=2023-01-13&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=2&rft_id=info:doi/10.3390%2Fcancers15020504&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon